379 related articles for article (PubMed ID: 30221051)
1. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V
Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
6. Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy.
Russo S; Feola S; Feodoroff M; Chiaro J; Antignani G; Fusciello M; D'Alessio F; Hamdan F; Pellinen T; Mölsä R; Tripodi L; Pastore L; Grönholm M; Cerullo V
Mol Ther Oncol; 2024 Mar; 32(1):200766. PubMed ID: 38596301
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.
Mostafa AA; Meyers DE; Thirukkumaran CM; Liu PJ; Gratton K; Spurrell J; Shi Q; Thakur S; Morris DG
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29914097
[TBL] [Abstract][Full Text] [Related]
8. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Oseledchyk A; Ricca JM; Gigoux M; Ko B; Redelman-Sidi G; Walther T; Liu C; Iyer G; Merghoub T; Wolchok JD; Zamarin D
Oncotarget; 2018 Jun; 9(47):28702-28716. PubMed ID: 29983890
[TBL] [Abstract][Full Text] [Related]
9. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Oweida A; Lennon S; Calame D; Korpela S; Bhatia S; Sharma J; Graham C; Binder D; Serkova N; Raben D; Heasley L; Clambey E; Nemenoff R; Karam SD
Oncoimmunology; 2017; 6(10):e1356153. PubMed ID: 29123967
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory.
Veinalde R; Pidelaserra-Martí G; Moulin C; Jeworowski LM; Küther L; Buchholz CJ; Jäger D; Ungerechts G; Engeland CE
Mol Ther Oncolytics; 2022 Mar; 24():43-58. PubMed ID: 34977341
[TBL] [Abstract][Full Text] [Related]
11. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Ylösmäki E; Ylösmäki L; Fusciello M; Martins B; Ahokas P; Cojoc H; Uoti A; Feola S; Kreutzman A; Ranki T; Karbach J; Viitala T; Priha P; Jäger E; Pesonen S; Cerullo V
Mol Ther Oncolytics; 2021 Mar; 20():459-469. PubMed ID: 33718594
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
17. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
[TBL] [Abstract][Full Text] [Related]
18. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
[TBL] [Abstract][Full Text] [Related]
19. Chimerization of the Anti-Viral CD8
Vile R; Webb M; van Vloten J; Evgin L; Sangsuwannukul T; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Yerovi MC; McNiven M; Monga S; Borad M; Roberts L
Res Sq; 2023 Nov; ():. PubMed ID: 38045348
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
